CSNK2A1 and osteosarcoma: In the univariate analysis of 26 osteosarcoma patients who received adjuvant chemotherapy, the expression of CSNK2A1 (OS; p = 0.008, RFS; p = 0.003) and pSIRT6 (OS; p = 0.015, RFS; p = 0.008) were significantly associated with OS and RFS (Table 4) (Figure 2).